REVIEWSkin autofluorescence as tool for cardiovascular and diabetes risk predictionSmit, Andries Jan; van de Zande, Saskia Corine; Mulder, Douwe Johannes Author Information Department of Internal Medicine, division of Vascular Medicine, University Medical Center Groningen, Groningen, The Netherlands Correspondence to Andries Jan Smit, MD, PhD, Department of Medicine, P.O. Box 30001, 9700 RB Groningen, The Netherlands. Tel: +31 50 3616161; e-mail: [email protected] Current Opinion in Nephrology and Hypertension ():10.1097/MNH.0000000000000835, September 14, 2022. | DOI: 10.1097/MNH.0000000000000835 Buy PAP Metrics Abstract Purpose of review Advanced glycation endproducts (AGE) have an important role in the development of chronic complications in diabetes mellitus and in renal failure. Skin autofluorescence (SAF) is a simple noninvasive optical technique to estimate AGE levels in the dermis. SAF increases with age, but rises more rapidly in diabetes and renal failure, and is also associated with, and a predictor of their complications. Recent findings In recent large population studies, SAF is a strong predictor of development of type 2 diabetes (T2D), and in persons with known diabetes of its complications. SAF also predicts new cardiovascular disease (CVD) and mortality not only in individuals with known type 2 diabetes but also in the general population. Summary SAF is a simple, powerful and independent predictor for development of type 2 diabetes (T2D), and also for cardiovascular disease and mortality in both persons with diabetes, and in the general population. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.